etoposide has been researched along with belinostat in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agama, K; Bates, SE; Giaccone, G; Komlodi-Pasztor, E; Luchenko, VL; Murphy, RF; Pommier, Y; Salcido, CD; Varticovski, L; Zhang, Y | 1 |
| Balasubramaniam, S; Bates, SE; Bryla, C; Ehrlich, S; Figg, WD; Goey, AK; Lee, MJ; Peer, CJ; Piekarz, R; Sissung, TM; Steinberg, SM; Tomita, Y; Trepel, JB | 1 |
| Balasubramaniam, S; Bates, SE; Bonner, WM; Bryla, C; Figg, WD; Fojo, T; Giaccone, G; Lee, MJ; Peer, CJ; Piekarz, RL; Rajan, A; Redon, CE; Tomita, Y; Trepel, JB | 1 |
2 trial(s) available for etoposide and belinostat
| Article | Year |
|---|---|
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.
Topics: Adult; Aged; Area Under Curve; Cisplatin; Etoposide; Female; Genotype; Glucuronosyltransferase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Sulfonamides | 2016 |
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Glucuronosyltransferase; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Sulfonamides; Treatment Outcome | 2018 |
1 other study(ies) available for etoposide and belinostat
| Article | Year |
|---|---|
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Depsipeptides; DNA Breaks, Double-Stranded; Drug Synergism; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Models, Theoretical; Phosphorylation; Small Cell Lung Carcinoma; Sulfonamides; Time Factors | 2011 |